Akebia Therap (AKBA)
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Akebia Therap Analyst Rating
View moreForecast & Rating
Sep 15, 2026Price forecast
$3.92326.75%
Forecast & RatingBuy
6analysts
- Strong buy66.67%
- Buy16.67%
- Hold16.67%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 2 days ago, 12:07 PM
Akebia doses first patient in Phase 2 ebribafusp trial for rare complement-mediated kidney diseases
- Unusual Whales · 2 days ago, 12:02 PM
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
- Market Beat · Sep 8 at 03:42 PM
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital
- PUBT · Sep 1 at 08:07 PM
Akebia grants new hire stock options for 8,400 shares at $0.92 each
- PUBT · Sep 1 at 12:02 PM
Akebia Therapeutics holds investor meetings at Wells Fargo Healthcare Conference
